Segall Bryant & Hamill, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Segall Bryant & Hamill, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $783,537 - $850,692	1,110 New	1,110 $800,000
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $637,106 - $803,995	1,110 New	1,110 $765,000
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $26,087 - $32,206	48 Added 4.52%	1,110 $700,000
Q3 2021 Nov 03, 2021	BUY	$574.03 - $680.96 $1,148 - $1,361	2 Added 0.19%	1,062 $642,000
Q2 2021 Aug 12, 2021	SELL	$472.8 - $558.54 $196,212 - $231,794	-415 Reduced 28.14%	1,060 $592,000
Q1 2021 May 13, 2021	BUY	$446.73 - $548.2 $185,392 - $227,503	415 Added 39.15%	1,475 $697,000
Q4 2020 Feb 12, 2021	SELL	$478.3 - $607.98 $478 - $607	-1 Reduced 0.09%	1,060 $512,000
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $24,172 - $31,552	-49 Reduced 4.41%	1,061 $661,000
Q4 2019 Feb 11, 2020	BUY	$274.13 - $376.51 $3,563 - $4,894	13 Added 1.19%	1,110 $416,000
Q2 2019 Aug 14, 2019	SELL	$299.6 - $414.82 $8,988 - $12,444	-30 Reduced 2.66%	1,097 $0
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $5,581 - $6,593	15 Added 1.35%	1,127 $0
Q4 2018 Feb 15, 2019	BUY	$335.82 - $403.04 $5,037 - $6,045	15 Added 1.37%	1,112 $415,000
Q2 2018 Aug 08, 2018	BUY	$284.6 - $344.99 $14,230 - $17,249	50 Added 4.78%	1,097 $0
Q1 2018 May 16, 2018	SELL	$315.82 - $393.78 $17,370 - $21,657	-55 Reduced 4.99%	1,047 $0
Q4 2017 Feb 15, 2018	BUY	$358.63 - $469.95 $19,724 - $25,847	55 Added 5.25%	1,102 $0
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $451,654 - $527,688	1,047	1,047 $0

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.